A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1 - Infected patients

HIV Clinical Trials

Volumn 2, Issue 2, 2001, Pages 97-107

  Smith, D ^a   Hales, G ^a   Roth, N ^a   Law, M ^a   Ray, J ^a   Druett, J ^a   Mitchell, J ^a   Mills, G ^a   Doong, N ^a   Franklin, R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral; Clinical trial; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ADULT; AGE; AGED; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035046656     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/CFYJ-26JF-VVRU-7AN8     Document Type: Article

References (31)

1. Report of the NIH panel to define principles of therapy of HIV infection
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
4. A trial of monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre
5. The effect of high dose saquinavir on viral load and CD4+ T-cell count in HIV-infected patients
6. Saquinavir soft-gel capsule formulation
7. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
8. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
9. Evaluation of the pharmacokinetic (PK) interaction between saquinavir and delavirdine in healthy volunteers
10. A short term study of safety, pharmacokinetic, and efficacy of ritonavir, an inhibitor of HIV-1 protease
11. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
12. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma
13. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
14. Antiretroviral drug resistance testing in adult HIV-1 infection
15. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
16. Acute hypersensitivity with delavirdine
17. Possible fatal interaction between protease inhibitors and methamphetamine
18. Clinical resistance patterns and response to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced patients
19. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1 positive patients heavily pretreated with nucleoside analogues and protease inhibitors
20. Baseline HIV drug resistance profile predicts response to ritonavirsaquinavir protease inhibitor therapy in a community setting
21. HIV-1 genotypic resistance patterns predict response to saquinavirritonavir therapy in patients in whom previous protease inhibitor therapy had failed
22. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
23. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates
24. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
25. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
26. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
27. Virological treatment failure to protease inhibitor therapy in an unselected cohort of HIV-infected patients
28. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
29. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
30. Accuracy of doctors estimates and patients statements on adherence to a drug regimen
31. Clinical and immunologic response without decrease in viral load in patients with AIDS after 24 months of highly active antiretroviral therapy